Investor search in Quimatryx

Quimatryx has hired NORGESTION to search for one or more partners to rise €3 Million in two planned financial rounds between 2018 and 2019. This amount will be used to develop Quimatryx compound QTX125 (selective inhibitor against HDAC6) to clinical phase I for mantle cell lymphoma.